Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | NSCLC | Research article

Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings

Authors: Milena Pązik, Katarzyna Michalska, Marta Żebrowska-Nawrocka, Izabela Zawadzka, Mariusz Łochowski, Ewa Balcerczak

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

The RAS family protooncogenes, including KRAS, NRAS and HRAS, encode proteins responsible for the regulation of growth, differentiation and survival of many cell types. The HRAS and KRAS oncogene mutations are well defined, however, the clinical significance of RAS expressions in non–small-cell lung cancer (NSCLC) is still uncertain.

Methods

A total of 39 whole blood samples of NSCLC (the investigated group), collected at three points of time: at the time of diagnosis, 100 days and 1 year after the surgery as well as 35 tissue samples obtained during the surgery were included in this study. HRAS and KRAS genes mRNA expression were assessed using quantitative real-time polymerase chain reaction techniques.

Results

Increased relative HRAS mRNA level in blood was found significantly more frequently in the group of smokers (p = 0.008). Patients with squamous cell carcinoma subtypes of NSCLC were more likely to show an overexpression of HRAS gene in blood, but not statistically significant (p = 0.065). In tumor tissue overexpression of HRAS gene was associated with adenocarcinoma subtype (p = 0.049). No statistically significant associations were found for the expression of KRAS with any clinicopathological parameters, except the age of patients, within the study. There were no differences between the relative HRAS and KRAS genes expression levels in blood samples taken from the same patients during the 3 observation points, as well as between blood collected from patients before surgery and tissue samples obtained during operation.

Conclusion

The potential associations between high HRAS expression levels, age, smoking status and histological type of cancer were observed, which emphasizes the need for further study of the RAS family. Therefore, subsequent research involving larger numbers of patients and a longer follow-up, as well as multicenter study are necessary to confirm our findings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Román M, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer. 2018;17(1):33.CrossRef Román M, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer. 2018;17(1):33.CrossRef
2.
go back to reference Blandin Knight S, et al. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9):170070.CrossRef Blandin Knight S, et al. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9):170070.CrossRef
3.
go back to reference Khan AQ, et al. RAS-mediated oncogenic signaling pathways in human malignancies. Semin Cancer Biol. 2019;54:1–13.CrossRef Khan AQ, et al. RAS-mediated oncogenic signaling pathways in human malignancies. Semin Cancer Biol. 2019;54:1–13.CrossRef
4.
go back to reference Marín-Ramos NI, Ortega-Gutiérrez S, López-Rodríguez ML. Blocking Ras inhibition as an antitumor strategy. Semin Cancer Biol. 2019;54:91–100.CrossRef Marín-Ramos NI, Ortega-Gutiérrez S, López-Rodríguez ML. Blocking Ras inhibition as an antitumor strategy. Semin Cancer Biol. 2019;54:91–100.CrossRef
5.
go back to reference Ferrer I, et al. KRAS-mutant non-small cell lung cancer: from biology to therapy. Lung Cancer. 2018;124:53–64.CrossRef Ferrer I, et al. KRAS-mutant non-small cell lung cancer: from biology to therapy. Lung Cancer. 2018;124:53–64.CrossRef
6.
go back to reference Murugan AK, Grieco M, Tsuchida N. RAS mutations in human cancers: roles in precision medicine. Semin Cancer Biol. 2019;59:23–35.CrossRef Murugan AK, Grieco M, Tsuchida N. RAS mutations in human cancers: roles in precision medicine. Semin Cancer Biol. 2019;59:23–35.CrossRef
7.
go back to reference Li S, Balmain A, Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat Rev Cancer. 2018;18(12):767–77.CrossRef Li S, Balmain A, Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat Rev Cancer. 2018;18(12):767–77.CrossRef
8.
go back to reference Lindsay CR, et al. KRAS: reasons for optimism in lung cancer. Eur J Cancer. 2018;99:20–7.CrossRef Lindsay CR, et al. KRAS: reasons for optimism in lung cancer. Eur J Cancer. 2018;99:20–7.CrossRef
9.
go back to reference Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8.CrossRef Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8.CrossRef
10.
go back to reference Castellano E, Santos E. Functional specificity of ras isoforms: so similar but so different. Genes Cancer. 2011;2(3):216–31.CrossRef Castellano E, Santos E. Functional specificity of ras isoforms: so similar but so different. Genes Cancer. 2011;2(3):216–31.CrossRef
11.
go back to reference Kodaz H, et al. Frequency of Ras Mutations (Kras, Nras, Hras) in Human Solid Cancer. EJMO. 2017;1(1):1–7. Kodaz H, et al. Frequency of Ras Mutations (Kras, Nras, Hras) in Human Solid Cancer. EJMO. 2017;1(1):1–7.
12.
go back to reference Cox AD, Der CJ. Ras history: the saga continues. Small GTPases. 2010;1(1):2–27.CrossRef Cox AD, Der CJ. Ras history: the saga continues. Small GTPases. 2010;1(1):2–27.CrossRef
13.
go back to reference Zinatizadeh MR, et al. The role and function of Ras-association domain family in Cancer: a review. Genes Dis. 2019;6(4):378–84.CrossRef Zinatizadeh MR, et al. The role and function of Ras-association domain family in Cancer: a review. Genes Dis. 2019;6(4):378–84.CrossRef
14.
go back to reference Banys-Paluchowski M, et al. Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients. Breast Cancer Res Treat. 2020;179(2):403–14.CrossRef Banys-Paluchowski M, et al. Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients. Breast Cancer Res Treat. 2020;179(2):403–14.CrossRef
15.
go back to reference Aran V, et al. A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients. Lung Cancer. 2018;116:7–14.CrossRef Aran V, et al. A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients. Lung Cancer. 2018;116:7–14.CrossRef
16.
go back to reference An SJ, et al. Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy. Cancer Gene Ther. 2014;21(3):110–4.CrossRef An SJ, et al. Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy. Cancer Gene Ther. 2014;21(3):110–4.CrossRef
17.
go back to reference Krishna A, et al. Does Harvey-Ras gene expression lead to oral squamous cell carcinoma? A clinicopathological aspect. J Oral Maxillofac Pathol. 2018;22(1):65–72.PubMedPubMedCentral Krishna A, et al. Does Harvey-Ras gene expression lead to oral squamous cell carcinoma? A clinicopathological aspect. J Oral Maxillofac Pathol. 2018;22(1):65–72.PubMedPubMedCentral
18.
go back to reference Wu XY, et al. Identification of HRAS as cancer-promoting gene in gastric carcinoma cell aggressiveness. Am J Cancer Res. 2016;6(9):1935–48.PubMedPubMedCentral Wu XY, et al. Identification of HRAS as cancer-promoting gene in gastric carcinoma cell aggressiveness. Am J Cancer Res. 2016;6(9):1935–48.PubMedPubMedCentral
19.
go back to reference Hirsch FR, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008;3(12):1468–81.CrossRef Hirsch FR, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008;3(12):1468–81.CrossRef
20.
go back to reference Lozar T, et al. The biology and clinical potential of circulating tumor cells. Radiol Oncol. 2019;53(2):131–47.CrossRef Lozar T, et al. The biology and clinical potential of circulating tumor cells. Radiol Oncol. 2019;53(2):131–47.CrossRef
22.
go back to reference Liang H, et al. Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. J Exp Clin Cancer Res. 2012;31:36.CrossRef Liang H, et al. Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. J Exp Clin Cancer Res. 2012;31:36.CrossRef
23.
go back to reference Zhou JD, et al. KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia. Oncotarget. 2017;8(39):66087–97.CrossRef Zhou JD, et al. KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia. Oncotarget. 2017;8(39):66087–97.CrossRef
24.
go back to reference Sugita S, et al. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer. Int J Oncol. 2018;53(2):725–36.PubMed Sugita S, et al. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer. Int J Oncol. 2018;53(2):725–36.PubMed
25.
go back to reference Wan X, Liu R, Li Z. The prognostic value of HRAS mRNA expression in cutaneous melanoma. Biomed Res Int. 2017;2017:5356737.PubMedPubMedCentral Wan X, Liu R, Li Z. The prognostic value of HRAS mRNA expression in cutaneous melanoma. Biomed Res Int. 2017;2017:5356737.PubMedPubMedCentral
26.
go back to reference Chen S, et al. Low expression of PKCα and high expression of KRAS predict poor prognosis in patients with colorectal cancer. Oncol Lett. 2016;12(3):1655–60.CrossRef Chen S, et al. Low expression of PKCα and high expression of KRAS predict poor prognosis in patients with colorectal cancer. Oncol Lett. 2016;12(3):1655–60.CrossRef
27.
go back to reference Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129(7):1287–92.CrossRef Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129(7):1287–92.CrossRef
Metadata
Title
Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings
Authors
Milena Pązik
Katarzyna Michalska
Marta Żebrowska-Nawrocka
Izabela Zawadzka
Mariusz Łochowski
Ewa Balcerczak
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-07858-w

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine